Analysts think JAZZ stock price could increase by 48%
Apr 03, 2025, 11:25 AM
-5.02%
What does JAZZ do
Jazz Pharmaceuticals Plc, headquartered in Dublin, focuses on developing treatments for narcolepsy, oncology, pain, and psychiatry, employing 2,800 staff since its IPO in 2012. Key products include Xywav, Xyrem, and Defitelio.
18 analysts think JAZZ stock price will increase by 47.63%. The current median analyst target is $186.66 compared to a current stock price of $126.44. The lowest analysts target is $151.50 and the highest analyst target is $241.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
